10-Q: Processa Pharmaceuticals Reports Third Quarter 2024 Results, Initiates Phase 2 Trial for NGC-Cap

Processa Pharmaceuticals reported a net loss of $3.38 million for the third quarter of 2024 and initiated a Phase 2 trial for its lead drug candidate, NGC-Cap.

Summary

• Processa Pharmaceuticals, a clinical-stage biopharmaceutical company, reported a net loss of $3.38 million for the three months ended September 30, 2024, and a net loss of $9.12 million for the nine months ended September 30, 2024.
• The company's research and development expenses increased to $2.29 million for the quarter and $5.56 million for the nine months, primarily due to costs associated with the Phase 1B trial for NGC-Cap and the initiation of the Phase 2 trial.
• General and administrative expenses were $1.14 million for the quarter and $3.76 million for the nine months.
• Processa had cash and cash equivalents of $2.89 million as of September 30, 2024.
• The company raised $6.3 million in net proceeds from a public offering in January 2024 and $931,000 from an at-the-market offering in July 2024.
• Processa initiated a Phase 2 trial for NGC-Cap in breast cancer on October 2, 2024.
• The company is seeking additional funding to continue its operations and clinical trials.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in its clinical trials and has raised some capital, the significant net losses, insufficient cash, and going concern uncertainty, along with the ongoing litigation, weigh heavily on the overall sentiment.

Positives

• The company successfully initiated a Phase 2 trial for NGC-Cap in breast cancer.
• The company raised additional capital through public and at-the-market offerings.
• The company has a clear strategic focus on advancing its pipeline of NGC oncology drugs.
• The company's regulatory science approach is aligned with the FDA's Project Optimus initiative.

Negatives

• The company reported a net loss of $3.38 million for the third quarter of 2024 and $9.12 million for the nine months ended September 30, 2024.
• The company has an accumulated deficit of $84.5 million as of September 30, 2024.
• The company's cash and cash equivalents are $2.89 million as of September 30, 2024, which is not sufficient to fund operations for the next twelve months.
• The company is dependent on additional funding to continue its operations and clinical trials.
• There is substantial doubt about the company's ability to continue as a going concern within one year.
• The company is in litigation with Elion regarding a license agreement.

Risks

• The company has a limited operating history and a history of losses.
• The company's ability to achieve profitability is uncertain.
• The company's ability to obtain adequate financing to fund its business operations is uncertain.
• The company's ability to secure required FDA or other governmental approvals for its product candidates is uncertain.
• The company faces competition from other products, technologies, and pricing.
• The company's licenses are subject to termination by the licensor in certain circumstances.
• The company is in litigation with Elion regarding a license agreement, which could adversely affect the business.
• The company may have to delay, reduce the scope of, or suspend its current or planned future clinical trial plans, or research and development programs if it is unable to obtain adequate financing.

Future Outlook

The company plans to raise additional funds through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. The company will continue to be dependent upon equity and/or debt financing until it is able to generate positive cash flows from its operations. The company anticipates its research and development costs will increase as it continues its Phase 2 trial for NGC-Cap and evaluates other NGC drugs in its portfolio.

Management Comments

• Management believes that Elion's claims regarding the termination of the license agreement are without merit.
• Management is focused on advancing the pipeline of NGC proprietary small molecule oncology drugs.
• Management believes that utilizing their Regulatory Science Approach provides them with distinct advantages.

Industry Context

The company's focus on next-generation chemotherapy drugs aligns with the industry trend of improving existing cancer treatments by modifying their metabolism and distribution. The company's approach is also in line with the FDA's Project Optimus initiative, which emphasizes the importance of determining the optimal dosage regimen for oncology drugs.

Comparison to Industry Standards

• The company's Phase 1B trial for NGC-Cap showed a 66.7% response rate (partial response and stable disease) in evaluable patients, compared to a 21% response rate reported for capecitabine monotherapy in metastatic colorectal cancer patients.
• The company's Phase 1B trial for NGC-Cap showed a progression-free survival of approximately 5 to 11 months, compared to 4.5 months reported for capecitabine monotherapy.
• The company's Phase 1B trial for NGC-Cap showed a 6% hand-foot syndrome rate, compared to an expected ~50% based upon published data for capecitabine.

Management Changes

Legal Proceedings

• The company is in litigation with Elion regarding a license agreement, with the company filing a complaint on July 5, 2024, and Elion filing an answer and counterclaims on August 14, 2024.

Related Party Transactions

• CorLyst, LLC reimburses the company for shared costs related to payroll, health insurance, and rent.

Stakeholder Impact

• Shareholders face dilution risk from potential future equity offerings.
• Employees may be impacted by potential delays or reductions in research and development programs due to funding constraints.
• Patients may benefit from the development of new and improved cancer treatments, but the success of these treatments is not guaranteed.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company will continue its Phase 2 trial of NGC-Cap in breast cancer.
• The company will continue to evaluate the other NGC drugs in its portfolio.
• The company will seek additional funding to continue its operations and clinical trials.
• The company will continue to pursue its rights under the license agreement with Elion.

Key Dates

Keywords

biopharmaceutical, oncology, clinical trials, NGC-Cap, cancer, research and development, FDA, financing, reverse stock split, net loss